Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing

Executive Summary

Amgen and Allergan have filed an EU marketing authorization application for their biosimilar version of Roche’s monoclonal antibody product for cancer, Avastin (bevacizumab). In doing so, they join a growing number of biosimilars awaiting approval by the European authorities.

Advertisement

Related Content

Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch
Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU
First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn
CHMP's November Recommendations Include Suliqua, Vemlidy And Afstyla
Bevacizumab Biosimilar Nears Market As Amgen Files First At FDA
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097800

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel